Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - VEGF Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03917472 KINGFISHER (CRTH258B2305) Diabetic macular edema Phase 3 500 Change in best-corrected visual acuity (BCVA) from baseline up to week 52 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Target Patients Patients with visual impairment due to diabetic macular edema Read-out Milesstone(s) Q3-2021 (Actual) Publication Publication planned for H1-2022 NCT04058067 KINGLET (CRTH258B2304) Diabetic macular edema Phase 3 268 Change in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with visual impairment due to diabetic macular edema 2023 Publication planned for 2023 98 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation